Association between metabolic syndrome and depressive symptoms in middle-aged adults: Results from the Whitehall II study

Tasnime N Akbaraly a PhD, Mika Kivimäki a PhD, Eric J Brunner a PhD, Tarani Chandola a PhD, Michael G Marmot a PhD, Archana Singh-Manoux a,b,c PhD, Jane E Ferrie a PhD.

(a) Department of Epidemiology and Public Health, University College London, WC1E 6BT, UK
(b) INSERM U687-IFR69, France
(c) Centre de Gérontologie, Hôpital Ste Périne, AP-HP, France

Address correspondence and reprint requests to:
Tasnime Akbaraly
Email: t.akbaraly@ucl.ac.uk


This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes Care in print and online at http://care.diabetesjournals.org.
Objective: Although it is possible that the association between depression and the metabolic syndrome is a “two-way street”, the metabolic syndrome as a predictor of depression has been little investigated. We examined whether the metabolic syndrome is associated with the onset of depressive symptoms in a cohort of middle-aged British civil servants.

Research Design and Methods: Analyses included 5232 participants (41-61 years) from the Whitehall II prospective cohort study. Depressive symptoms were assessed in 1991-93 and again 6-years later using the depression subscale from the 30-item General Health Questionnaire. Metabolic syndrome was assessed in 1991-93, according to National Cholesterol Education Program criteria.

Results: Presence of the metabolic syndrome was associated with an increased risk of future depressive symptoms, odds ratio=1.38 [95% Confidence Interval, 1.02-1.96] after adjustment for potential confounders. Of the 5 components, only central obesity, high triglyceride levels and low HDL cholesterol levels predicted depressive symptoms. These components explained most of the association between the metabolic syndrome and the onset of depressive symptoms.

Conclusion: Our results suggest that the metabolic syndrome, in particular the obesity and dyslipidemia components, is predictive of depressive symptoms.
Evidence of an association between depression and cardiovascular diseases (CVD) (1; 2) has led some studies to investigate whether the metabolic syndrome may constitute an explanatory mechanism. The metabolic syndrome is defined as a clustering of risk factors which predispose an individual to cardiovascular morbidity and mortality (3; 4). It is characterised by elevated abdominal obesity, high triglycerides, high blood pressure, high fasting glucose and low high-density lipoproteins (HDL) cholesterol, and represents an important risk factor for CVD (5). Cross-sectional studies have shown an association between depression and the metabolic syndrome in young adults (6) and in middle aged populations (7-9). Cross-sectional associations between depressive symptoms and individual components of the metabolic syndrome have been observed in a North American study of elderly male twins, (10) but were not evident in a middle-aged cohort from northern Finland (11). The focus of longitudinal studies essentially has been to investigate whether depression predicts the metabolic syndrome and some have shown that, in middle aged populations, depressive symptoms appear to be associated with an increased risk of the metabolic syndrome in women but not in men (12; 13).

Although in most existing research the assumption has been that depression predicts the metabolic syndrome, depression could also be a consequence of the metabolic syndrome. To date, this reverse association has been little investigated. However, a “two-way street” between depression and the metabolic syndrome was suggested by findings from a population-based prospective cohort study in which women with the metabolic syndrome in childhood and adulthood had the highest level of depressive symptoms in adulthood (14). This finding was not observed for men. Further evidence was provided from a cohort of middle aged women, in which Raikkonen et al. showed that anger and anxiety increased in response to the metabolic syndrome (12). Only one report published recently has investigated the metabolic syndrome as a risk factor for depressive symptoms in middle aged adults. It showed that the metabolic syndrome may be an important factor for the development of depression in women but not in men (15).

Our objective is to investigate prospectively whether the metabolic syndrome is associated with the onset of depressive symptoms in a cohort of middle-aged British adults free of such symptoms at baseline, after taking into account potential confounders.

**RESEARCH DESIGN AND METHODS**


Assessment of metabolic syndrome at phases 3 and 5: The metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program (NCEP) (17), based on the presence of 3 or
Metabolic syndrome and depressive symptoms

more of the following: waist circumference >102 cm in men and >88 cm in women; serum triglycerides ≥1.7 mmol/L; HDL cholesterol <1.04 mmol/L in men and < 1.29 mmol/L in women; blood pressure ≥130 mmHg /≥85 mmHg systolic over diastolic pressure; fasting glucose ≥6.1 mmol/L. Waist circumference was taken as the smallest circumference below the costal margin. Resting blood pressure was measured using the Hawksley Random Zero Sphygmomanometer. Serum triglycerides, HDL cholesterol and fasting blood glucose were analyzed as previously described (18).

Assessment of depressive symptoms at phases 3 and 5: We assessed depressive symptoms using the four-item depression subscale of the 30-item General Health Questionnaire (GHQ) (19). The items, obtained on the basis of factor analysis and comparison with the items of the depression subscale of the 28 item GHQ (20), are: “thinking of yourself as a worthless person”, “felt life is entirely hopeless”, “felt life isn’t worth living”, “found at times you couldn’t do anything because your nerves were too bad”. All items were scored on a Likert scale from 0–3 and then summed (range 0-12). Respondents were categorised as free of depressive symptoms if they scored 0–3 or having depressive symptoms if they scored 4 or more. New onset depressive symptoms refers to participants who developed symptoms of depression between phases 3 and 5, after excluding participants with depressive symptoms at phase 3. Depressive symptoms, assessed with GHQ, cannot be equated with clinically diagnosed depression (21).

Assessment of covariates at phase 3: Socio-demographic variables consisted of age, sex, ethnicity (white/ South Asian/ black), marital status, employment grade and education. Employment grade, defined on the basis of salary, ranges from 1 to 3, with grade 1 representing the highest level and grade 3 the lowest. Educational attainment was grouped into five levels (no academic qualification, lower secondary, higher secondary, university degree, higher university degree). Health behaviors measured were current smoker (yes/no), alcohol consumption (grams/day), and intensity of physical activity (based on questions on frequency and duration of physical activity and categorised as “high”, “medium” and “low”). Prevalent coronary heart disease (CHD) identified using clinically verified events, included non fatal myocardial infarction and definite angina as described previously (22).

Statistical Methods—Logistic regression was used to model the association between the metabolic syndrome and each of its components at phase 3 and the onset of depressive symptoms between phase 3 and phase 5. In the first model (Model 1), the analyses were adjusted for age, sex and ethnicity; in the second model (Model 2) they were also adjusted for employment grade, educational level, marital status, smoking habit, alcohol consumption, physical activity and CHD. Interactions between the metabolic syndrome and the covariates (including sex) were tested and were not found to be statistically significant at p<0.05.

To assess the extent to which components of the metabolic syndrome drive the association with depressive symptoms we calculated the percentage attenuation in the metabolic syndrome-depressive symptoms association after the components separately associated with depressive symptoms were added to the model. The percentage attenuation in the association between metabolic syndrome and depressive symptoms was determined using the formula: 

\[
\% = \left[ \left( \frac{\beta_x - \beta_{x \text{ adjusted for } w}}{\beta_x} \right) \right] \times 100,
\]

where \( \beta_x \) is the beta coefficient estimated from the logistic regression model.

In order further to understand the role of the metabolic syndrome as a risk factor for
the onset of depressive symptoms, we performed analyses to explore whether its components act synergistically by testing interactions between them. We used a backward elimination approach that removed all of 5-, 4-, 3- and 2-way interaction terms with p>0.05 from a saturated model that included all of the metabolic syndrome components and their interaction terms. A new variable combining obesity, high triglyceride and low HDL cholesterol components (7 modalities: 0=none of the component, 1= only obesity, 2= only high triglyceride; 3= only low HDL cholesterol, 4= obesity and high triglyceride, 5= obesity and low HDL cholesterol, 6= high triglyceride and low HDL cholesterol, 7= all three components) was constructed to test specifically the combined effects of these three components on onset of depressive symptoms.

In sensitivity analyses, we excluded participants with CHD at phase 3 to explore the contribution of CHD to the association between the metabolic syndrome and onset of depressive symptoms. To assess potential bidirectional effects, we excluded participants free of the metabolic syndrome at phase 3 and we performed logistic regression analyses examining associations between depressive symptoms at phase 3 and onset of the metabolic syndrome between phase 3 and phase 5. All analyses were conducted using the SAS software, version 9 (SAS Institute).

RESULTS

Overall, 7263 individuals participated in Phase 5. However, complete data on depressive symptoms at phases 3 and 5, the metabolic syndrome and all the covariates were available for 5562 participants (1604 women and 3958 men) aged 49.5 ±6.1 years at phase 3. Three hundred and thirty of these participants had depressive symptoms at phase 3 and were excluded in order to identify new onset depressive symptoms between phase 3 and phase 5. Compared with those excluded, participants included in the analysis (n=5232) were more likely to be men (71.5% vs. 66.2%) and younger (49.6 ± 6.08 vs. 49.9 ± 6.06 years). However they did not differ on educational level (% of participants with no academic qualification: 13.1 % for participants included vs. 13.7% for those excluded) or prevalence of the metabolic syndrome (10.4 % for participants included vs. 11.4 % for those excluded). Prevalence of the metabolic syndrome in participants who already had depressive symptoms at phase 3 was 9.7% and was not significantly different from that in participants free from depressive symptoms both at phase 3 and at phase 5 (10.2%).

Characteristics of the participants as a function of the presence of metabolic syndrome are shown in Table 1. Prevalence of the metabolic syndrome was 10.4 % (n=547). Compared to participants without the metabolic syndrome, the proportion of participants with the metabolic syndrome was lower in women and in “white participants”, but was higher in those with a low education level and among those who had low physical activity. As expected, participants with the metabolic syndrome had higher waist circumference, triglycerides, blood pressure and fasting blood glucose levels and a lower HDL cholesterol concentration compared to participants without the metabolic syndrome.

Four hundred and twenty eight participants (8.2%) developed depressive symptoms after phase 3, 7.8% of the men and 9.2% of the women. New onset depressive symptoms were more common among those who had the metabolic syndrome at phase 3 (13.5 % vs. 10.2%). Furthermore, a higher rate of new onset depressive symptoms was observed in participants with the central obesity (14.3% vs. 10.4%), high triglycerides (29.4 % vs. 24.9%) and low HDL-cholesterol (22.7 % vs. 17.8 %) components of the metabolic syndrome.
Table 2 shows multivariate models of the association between the metabolic syndrome at phase 3 and onset of depressive symptoms between phase 3 and phase 5. In analyses adjusted for sex, ethnicity and age, the odds of new-onset depressive symptoms was 1.47 [95% CI: 1.09-1.99] times higher for participants with the metabolic syndrome than for those without. This association remained statistically significant after further adjustment for other socio-demographic factors, health behaviour and CHD; odds ratio (OR) = 1.38 [1.02-1.87]. Multivariate analyses of the association between each component of the metabolic syndrome and onset of depressive symptoms showed that of the 5 components, only central obesity, high triglyceride levels and low HDL cholesterol levels were related to a greater odds of onset of depressive symptoms between phase 3 and phase 5, while there was no evidence of an association between hypertension and new-onset depressive symptoms. Unexpectedly, participants with elevated fasting blood glucose levels were less likely to develop depressive symptoms during the 6-years follow-up. In order to examine if the components of the metabolic syndrome had an independent effect we included them all simultaneously in a model that included only participants with no missing data on any of the metabolic syndrome components (n=4983 participants with 401 new onset depressive symptoms). None of the components remained significantly associated with the onset of depressive symptoms (obesity component: OR=1.28 [0.92; 1.77], high triglycerides component: OR=1.20 [0.93;1.56], low HDL cholesterol: OR=1.19 [0.90;1.56], hypertension: OR=0.97 [0.77;1.21], high fasting blood glucose: OR=0.57 [0.32;1.02]).

The fact that nearly half the participants with metabolic syndrome were obese (49.8%) raises the possibility that the association we observed between the metabolic syndrome and depressive symptoms is driven mainly by obesity. The percentage attenuation of the association between metabolic syndrome and depressive symptoms by its individual components was as follows: 37.5 % for obesity, 38.0% for triglycerides, and 23.4% for low HDL cholesterol. All three components together explained 93 % of the association. Obesity explained only 20.4% of the relationship between high triglycerides and depressive symptoms and 17.8% of the association between low HDL cholesterol and depressive symptoms (Table 3). These findings provide support for the hypothesis that the association between the metabolic syndrome and depressive symptoms is partly driven by central obesity, but that dyslipidemia is also a major driver.

To test for synergistic effects between the components of metabolic syndrome on depressive symptoms, we examined multiple interaction terms but none of these were statistically significant (results not shown but available on request). However, using a unique variable with all possible combinations of the obesity, high triglycerides and low HDL components, we found that participants with all three components were at the greatest risk of new-onset depressive symptoms, odds ratio 2.71 (95% CI: 1.73-4.24).

**Sensitivity analyses:** Exclusion of participants with CHD at phase 3 (n=136) had little effect on the results: After adjusting for sex, ethnicity and age, the odds of new-onset depressive symptoms were 1.37 [1.00-1.87] times higher for participants with the metabolic syndrome than for those without. No support was found for the hypothesis that depressive symptoms were a consequence rather than a cause of the metabolic syndrome as there was no association between presence of depressive symptoms at phase 3 and new onset cases of the metabolic syndrome in participants free of metabolic syndrome at
phase 3, odds ratio 0.89 (95% CI 0.60-1.33),
p=0.57 after controlling for sex, age and
etnicity and 0.81 (95% CI 054-1.22) after
adjusting for socio-demographic factors,
health behaviours and CHD (results not
shown but available on request).

CONCLUSIONS
We examined associations between
presence of the metabolic syndrome and the
onset of depressive symptoms in a middle
aged population free of such symptoms at
baseline. After adjusting for demographic
measures, socio-economic factors, health
behaviours and prevalent coronary heart
disease, participants with the metabolic
syndrome had a higher risk of developing
depressive symptoms six years later. Of the
components of the metabolic syndrome,
central obesity, high triglycerides and low
HDL cholesterol were the main contributing
factors to this association. There was no
evidence to support bidirectional associations
between the metabolic syndrome and
depressive symptoms.

Among the 5562 participants in this
study in 1993, prevalence of the metabolic
syndrome according to NCEP criteria was
10.4%. Similar levels of prevalence were
found in a cohort of healthy middle aged
women in the Healthy Women study (9.3% in
1988) (13) and in a cohort of middle aged
men participating in the Kuopio Ischemic
Heart Disease Risk Factor Study (11% in
1989) (23). Prevalent CHD is a potential
source of depression, but in the present study
the association between the metabolic
syndrome and new-onset depressive
symptoms remained significant after
controlling for prevalent CHD, and in a sub-
cohort that excluded participants with this
disease. This suggests that the association
between the metabolic syndrome and
depressive symptoms is not driven by
depressive symptoms generated by manifest
CHD.

Our findings are consistent with the
hypothesis that depressive symptoms may be
a consequence rather than a cause of the
metabolic syndrome. Prevalence of the
metabolic syndrome was no higher in
participants with depressive symptoms at
baseline than among participants who did not
have such symptoms at baseline or at follow-
up. This lack of evidence was confirmed in
further analyses showing no association
between presence of depressive symptoms at
baseline and development of the metabolic
syndrome during the follow-up. A
 corresponding finding was observed in the
Northern Finland 1966 Birth cohort Study in
which the metabolic syndrome defined
according NCEP criteria was not associated
with depressiveness and anxiousness in 31-
year-old adults (11).

In a middle-aged population-based
sample, Koponen et al found the metabolic
syndrome, assessed using NCEP criteria, was
associated with a higher probability of
depressive symptoms (measured using the
Beck Depression Inventory) after a 7-year
follow-up in women but not in men (15). In
another Finnish population-based study
women with the metabolic syndrome in
childhood had a higher mean depressive
symptom score (Beck Depression Inventory)
in adulthood but again no association was
found in men (14). The reasons why these
associations should be sex-specific remain
unclear and are in contrast to our findings of
an association between the metabolic
syndrome and onset of depressive symptoms
6 years later in both sexes.

An important aspect of our study is the
exploration of the relationship between each
component of the metabolic syndrome and
subsequent onset of depressive symptoms.
We found good evidence that central obesity
and abnormal lipids were associated with the
onset of depressive symptoms. However, the
hypertension component was not associated
with subsequent depressive symptoms and,
unexpectedly, high levels of fasting blood glucose were associated with a lower rather than a higher probability of depressive symptoms. The results for central obesity are in concordance with the Alameda County Study which showed that obesity was associated with an increased risk of depression 5-years later (24). According to Ross et al. (25) one explanation of the obesity-depression relationship could be devaluation and stigma which may cause overweight and obese individuals to suffer from lower self-esteem and a higher level of depression. Another potential explanation involves unsuccessful weight control by dieting among obese and overweight people which could be more stressful than the obesity per se (25).

It has been argued that the metabolic syndrome is driven almost entirely by central obesity. Our results do not support this position in relation to either the basic association between the metabolic syndrome and depressive symptoms, or the associations between the high triglycerides and low HDL cholesterol components of the metabolic syndrome and the onset of depressive symptoms. Thus, the metabolic syndrome-depressive symptoms association does not appear to be simply an artefact of the preponderance of obesity in individuals with the syndrome. While we found no evidence of synergy among the metabolic syndrome components in predicting depressive symptoms, our results showed that central obesity, high triglycerides and low HDL cholesterol components had a cumulative effect on their onset. These findings suggest that a combination of central obesity and abnormal lipids constitutes a risk factor for the onset of depressive symptoms. Further research on prospective associations between components of the metabolic syndrome and the development of depression is needed to confirm our findings and to explore the mechanisms that underlie the association.

Our study has several potential limitations. First, depressive symptoms were measured using a short scale that is not a measure of clinically recognized psychiatric disorder. Although the symptom scale is reliable it does not indicate the severity or the chronicity of the depression. A second drawback concerns the limited generalizability of our findings. Whitehall II study participants are mainly white, office-based civil servants who are not fully representative of the British population (16). Third, despite the extensive level of adjustment in our analyses, with observational data the possibility remains that unmeasured confounders may explain part of the association between the metabolic syndrome and depressive symptoms.

In conclusion, this is apparently the first study to show that the probability of new onset depressive symptoms 6-years later is higher amongst men and women with the metabolic syndrome; an association that remains after taking into account a large range of potential confounders. Further research is needed to examine whether prevention of the metabolic syndrome, in particular its obesity and dyslipidemia components, might reduce the onset of depressive symptoms.

ACKNOWLEDGEMENTS

We thank all of the participating civil service departments and their welfare, personnel, and establishment officers; the British Occupational Health and Safety Agency; the British Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and all members of the Whitehall II study team.

MK is supported by the Academy of Finland (projects 117604, 124322 and 124271). AS-M is supported by a “European Young Investigator Award” from the European Science Foundation. MM is supported by an MRC research professorship. J.E.F. is supported by the Medical Research
Council (Grant number G8802774). The Whitehall II study has been supported by grants from the British Medical Research Council (MRC); the British Heart Foundation; the British Health and Safety Executive; the British Department of Health; the National Heart, Lung, and Blood Institute (grant HL36310); the National Institute on Aging (grant AG13196); the Agency for Health Care Policy and Research (grant HS06516); and the John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socioeconomic Status and Health.

Authors have no conflict of interest to disclose.
Metabolic syndrome and depressive symptoms

REFERENCES

Table 1: Characteristics of Whitehall participants according to presence of the metabolic syndrome; phase 3 (1991-1993)

<table>
<thead>
<tr>
<th></th>
<th>Metabolic syndrome *</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>N=4685</td>
</tr>
<tr>
<td>% or M ± SD**</td>
<td>% or M ± SD**</td>
</tr>
<tr>
<td>Women</td>
<td>29.5</td>
</tr>
<tr>
<td>Age (year)</td>
<td>49.4 ± 6.1</td>
</tr>
<tr>
<td>White participants</td>
<td>93.7</td>
</tr>
<tr>
<td>Single or Divorced</td>
<td>19.8</td>
</tr>
<tr>
<td>Low employment grade</td>
<td>12.5</td>
</tr>
<tr>
<td>No academic level or Lower secondary</td>
<td>45.2</td>
</tr>
<tr>
<td>Current Smoker</td>
<td>11.5</td>
</tr>
<tr>
<td>Alcohol consumption (ml/day)</td>
<td>12.5 ±14.1</td>
</tr>
<tr>
<td>Low level of physical activity</td>
<td>23.8</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>84.2±10.5</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>119.2±12.9</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>78.8±8.9</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>1.48±0.40</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>1.26±0.83</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>5.18±0.53</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>2.3</td>
</tr>
</tbody>
</table>

* Diagnosis of the metabolic syndrome was based on the NCEP definition (17)
** For continuous variables, means + standard deviations are given.
**Table 2:** Association between the metabolic syndrome at phase 3 and the onset of depressive symptoms between phase 3 (1991-93) and phase 5 (1997-99)

<table>
<thead>
<tr>
<th>Predictor</th>
<th>OR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic syndrome, (n=5232, 428 new-onset of depressive symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>1.47</td>
<td>1.09-1.99</td>
<td>0.01</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.38</td>
<td>1.02-1.87</td>
<td>0.04</td>
</tr>
<tr>
<td>Central obesity component, (n=5182, 424 new-onset of depressive symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>1.50</td>
<td>1.11-2.01</td>
<td>0.007</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.42</td>
<td>1.06-1.91</td>
<td>0.02</td>
</tr>
<tr>
<td>High triglyceride component, (n=5232, 428 new-onset of depressive symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>1.36</td>
<td>1.09-1.71</td>
<td>0.007</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.30</td>
<td>1.03-1.63</td>
<td>0.02</td>
</tr>
<tr>
<td>Low HDL cholesterol component, (n=5232, 428 new-onset of depressive symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>1.33</td>
<td>1.04-1.69</td>
<td>0.02</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.26</td>
<td>0.98-1.61</td>
<td>0.07</td>
</tr>
<tr>
<td>Hypertension component, (n=5232, 428 new-onset of depressive symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>1.06</td>
<td>0.86-1.31</td>
<td>0.57</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.05</td>
<td>0.85-1.30</td>
<td>0.66</td>
</tr>
<tr>
<td>High Fasting blood glucose component, (n=5049, 406 new-onset of depressive symptoms)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1</td>
<td>0.58</td>
<td>0.33-1.04</td>
<td>0.07</td>
</tr>
<tr>
<td>Model 2</td>
<td>0.57</td>
<td>0.32-1.02</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Results of logistic regression analyses expressed as Odds Ratios (OR) with 95 % Confidence Intervals (CI).

Model 1: adjusted for sex, age at phase 3 and ethnicity
Model 2: As Model 1+ adjusted for education, employment grade, marital status, smoking habits, alcohol consumption, physical activity, CHD

**Table 3:** Contribution of the obesity, high triglycerides and low HDL cholesterol components of the metabolic syndrome to the association between the metabolic syndrome and the onset of depressive symptoms

<table>
<thead>
<tr>
<th>Predictor</th>
<th>β</th>
<th>SE</th>
<th>Reduction in effect (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each component alone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>0.409</td>
<td>0.150</td>
<td>-</td>
</tr>
<tr>
<td>High triglyceride</td>
<td>0.294</td>
<td>0.116</td>
<td>-</td>
</tr>
<tr>
<td>Low HDL cholesterol</td>
<td>0.263</td>
<td>0.125</td>
<td>-</td>
</tr>
<tr>
<td>High triglycerides adjusted for obesity</td>
<td>0.234</td>
<td>0.120</td>
<td>20.4</td>
</tr>
<tr>
<td>HDL cholesterol adjusted for obesity</td>
<td>0.216</td>
<td>0.127</td>
<td>17.9</td>
</tr>
<tr>
<td>All three components included simultaneously in the model</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>0.322</td>
<td>0.156</td>
<td>21.3</td>
</tr>
<tr>
<td>High triglycerides</td>
<td>0.184</td>
<td>0.130</td>
<td>37.4</td>
</tr>
<tr>
<td>Low HDL cholesterol</td>
<td>0.143</td>
<td>0.137</td>
<td>45.6</td>
</tr>
<tr>
<td>Metabolic syndrome alone</td>
<td>0.389</td>
<td>0.153</td>
<td>-</td>
</tr>
<tr>
<td>Metabolic syndrome adjusted for obesity</td>
<td>0.250</td>
<td>0.175</td>
<td>35.7</td>
</tr>
<tr>
<td>Metabolic syndrome adjusted for triglyceride</td>
<td>0.241</td>
<td>0.186</td>
<td>38.0</td>
</tr>
<tr>
<td>Metabolic syndrome adjusted for HDL cholesterol</td>
<td>0.298</td>
<td>0.178</td>
<td>23.4</td>
</tr>
</tbody>
</table>

β: logistic regression coefficient.
Analyses performed on 5169 participants (423 new onset depressive symptoms)
*Compared with a model not adjusted for the factor.